HC Wainwright Forecasts Lifeward’s Q2 Earnings (NASDAQ:LFWD)

Lifeward Ltd. (NASDAQ:LFWD) – Stock analysts at HC Wainwright dropped their Q2 2026 EPS estimates for Lifeward in a research note issued on Tuesday, May 26th. HC Wainwright analyst S. Ramakanth now forecasts that the company will post earnings of ($1.49) per share for the quarter, down from their prior estimate of ($0.33). HC Wainwright currently has a “Buy” rating and a $10.00 price objective on the stock. The consensus estimate for Lifeward’s current full-year earnings is ($1.14) per share. HC Wainwright also issued estimates for Lifeward’s Q3 2026 earnings at ($0.42) EPS, Q4 2026 earnings at ($0.40) EPS, FY2026 earnings at ($4.27) EPS, FY2027 earnings at ($1.72) EPS, FY2028 earnings at ($0.83) EPS and FY2029 earnings at ($0.64) EPS.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Lifeward in a research note on Tuesday, April 21st. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, Lifeward currently has a consensus rating of “Hold” and a consensus target price of $10.00.

Lifeward Stock Performance

NASDAQ LFWD opened at $7.28 on Thursday. The firm’s fifty day moving average price is $6.90 and its two-hundred day moving average price is $7.08. The stock has a market cap of $20.46 million, a PE ratio of -0.37 and a beta of 0.36. Lifeward has a fifty-two week low of $4.14 and a fifty-two week high of $15.12. The company has a debt-to-equity ratio of 1.16, a quick ratio of 1.82 and a current ratio of 2.40.

Lifeward (NASDAQ:LFWD) last posted its earnings results on Friday, May 15th. The company reported ($6.70) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.18) by ($5.52). The company had revenue of $3.92 million for the quarter, compared to the consensus estimate of $5.78 million. Lifeward had a negative return on equity of 243.14% and a negative net margin of 123.66%.

Hedge Funds Weigh In On Lifeward

A number of hedge funds have recently modified their holdings of the business. Virtu Financial LLC lifted its holdings in shares of Lifeward by 158.0% during the fourth quarter. Virtu Financial LLC now owns 60,474 shares of the company’s stock worth $35,000 after purchasing an additional 37,037 shares during the period. Jane Street Group LLC lifted its holdings in shares of Lifeward by 77.3% during the fourth quarter. Jane Street Group LLC now owns 68,631 shares of the company’s stock worth $40,000 after purchasing an additional 29,927 shares during the period. HRT Financial LP lifted its holdings in shares of Lifeward by 149.7% during the fourth quarter. HRT Financial LP now owns 49,081 shares of the company’s stock worth $28,000 after purchasing an additional 29,423 shares during the period. Finally, Citadel Advisors LLC lifted its holdings in shares of Lifeward by 1,271.8% during the third quarter. Citadel Advisors LLC now owns 214,006 shares of the company’s stock worth $152,000 after purchasing an additional 198,406 shares during the period. Institutional investors and hedge funds own 26.76% of the company’s stock.

Key Stories Impacting Lifeward

Here are the key news stories impacting Lifeward this week:

• Neutral Sentiment: HC Wainwright maintained a Buy rating and $10 target price on Lifeward, indicating the firm still sees upside potential despite the lower earnings outlook.
• Neutral Sentiment: The analyst also raised its FY2030 EPS estimate to $3.20 from $2.90, suggesting longer-term earnings potential may be improving. Lifeward analyst update
• Negative Sentiment: HC Wainwright lowered near-term EPS estimates for Lifeward, including Q2 2026 to a loss of $1.49 per share, Q3 2026 to a loss of $0.42, and Q4 2026 to a loss of $0.40, signaling weaker expected performance in the coming quarters. Lifeward analyst update
• Negative Sentiment: The firm also slashed FY2026 EPS expectations to a loss of $4.27 per share, which could reinforce investor concern about continued losses and cash burn. Lifeward analyst update
• Negative Sentiment: FY2027 and FY2028 EPS estimates were also reduced, extending the weaker earnings trend into future periods and potentially limiting sentiment toward the stock. Lifeward analyst update

Lifeward Company Profile

ReWalk Robotics Ltd., a medical device company, designs, develops, and commercializes technologies that enable mobility and wellness in rehabilitation and daily life for individuals with physical and neurological conditions in the United States, Europe, the Asia-Pacific, and internationally. It offers ReWalk personal exoskeleton and rehabilitation exoskeleton devices; ReStore, a soft exo-suit intended for use in the rehabilitation of individuals with lower limb disability due to stroke; AlterG Anti-Gravity System for use in physical and neurological rehabilitation and athletic training; MyoCycle devices; and ReBoot, a personal soft exo-suit for home and community use by individuals post-stroke.